Behenic Acid

Behenic Acid

SCHEMBL875975

C=CCOC(=O)CCCCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCCCCCC(=O)O

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.87
PAM P19021 2/20 0.59
GPR84 Q9NQS5 7/20 0.57
PPARG P37231 7/20 0.57
PPARD Q03181 7/20 0.57
PPARA Q07869 7/20 0.57
HDAC11 Q96DB2 5/20 0.57
PTPN1 P18031 3/20 0.57
ALDH1A1 P00352 2/20 0.57
TLR2 O60603 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
FABP4 P15090 2/20 0.57
KMT2A Q03164 2/20 0.57
SLC22A6 Q4U2R8 1/20 0.57
SLC22A8 Q8TCC7 1/20 0.57
MEN1 O00255 1/20 0.57
ESR1 P03372 1/20 0.57
ALOX15 P16050 1/20 0.57
PDE4A P27815 1/20 0.57
PDE3A Q14432 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Allyl Octadecanoate SCHEMBL28396519 1.00 TSHR (0.87) TSHRPAMGPR84PPARGPPARD
Allyl Heptanoate SCHEMBL28325536 1.00 TSHR (0.87) TSHRPAMGPR84PPARGPPARD
Dodecanoate SCHEMBL28078900 1.00 TSHR (0.87) TSHRPAMGPR84PPARGPPARD
Allyl Hexanoate SCHEMBL7023588 0.98 TSHR (0.83) TSHRPAMGPR84PPARGPPARD
Allyl Octadecanoate SCHEMBL21611732 0.93 TSHR (0.87) TSHRPAMGPR84PPARGPPARD
Allyl Heptanoate SCHEMBL20820 0.93 TSHR (1.00) TSHRPAMALDH1A1KMT2AMEN1
Allyl Heptanoate SCHEMBL4147097 0.93 TSHR (1.00) TSHRPAMALDH1A1KMT2AMEN1
SCHEMBL440501 0.93 TSHR (1.00) TSHRPAMALDH1A1KMT2AMEN1
Allyl Octanoate SCHEMBL126629 0.93 TSHR (1.00) TSHRPAMALDH1A1KMT2AMEN1
SCHEMBL3503097 0.93 TSHR (1.00) TSHRPAMALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10555878-B2 Solid antiperspirant and/or deodorant composition in the form of a water-in-oil emulsion based on silicone emulsifiers and on waxes; method for treating body odours L'OREAL (FR) 2020-02-11 US disclosed
EP-2221039-B1 Antiperspirant compositions UNILEVER PLC NO 41424 (GB) 2017-11-22 EP disclosed
EP-2340009-B1 ANTIPERSPIRANT COMPOSITIONS UNILEVER PLC (GB) 2017-04-19 EP disclosed
EP-2181691-B1 Antiperspirant compositions UNILEVER PLC (GB) 2016-12-21 EP disclosed
EP-2181692-B1 Antiperspirant compositions UNILEVER PLC (GB) 2016-09-28 EP disclosed
EP-2229135-B1 SOLID ANTIPERSPIRANT AND/OR DEODORANT COMPOSITION IN THE FORM OF A WATER-IN-OIL EMULSION BASED ON SILICONE EMULSIFIERS AND ON WAXES; METHOD FOR TREATING BODY ODOURS ORÉAL L (FR) 2015-12-02 EP disclosed
US-9095531-B2 Antiperspirant compositions CONOPCO, INC. (US) 2015-08-04 US disclosed
US-9060957-B2 2015-06-23 US disclosed
US-20140193471-A1 SOLID ANTIPERSPIRANT AND/OR DEODORANT COMPOSITION IN THE FORM OF A WATER-IN-OIL EMULSION BASED ON SILICONE EMULSIFIERS AND ON WAXES; METHOD FOR TREATING BODY ODOURS L'OREAL (FR) 2014-07-10 US disclosed
US-8673327-B2 Solid antiperspirant and/or deodorant composition in the form of a water-in-oil emulsion based on silicone emulsifiers and on waxes; method for treating body odours L'OREAL (FR) 2014-03-18 US disclosed
EP-1280502-B1 COSMETIC COMPOSITIONS UNILEVER PLC (GB) 2005-08-24 EP disclosed
EP-1304999-A1 ANTIPERSPIRANT FORMULATIONS UNILEVER PLC (GB) 2003-05-02 EP disclosed
US-20020039563-A1 Antiperspirant formulations UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC 2002-04-04 US disclosed
US-6361765-B1 COMPOSITION COMPRISING PARTICULATE ANTIPERSPIRANT ACTIVE, ANHYDROUS LIQUID CARRIER AND STRUCTURANT OR THICKNENER COMPRISING ORGANIC WAX HAVING SPECIFIED MELTING POINT, AT LEAST 60% OF WHICH IS PROVIDED BY ALIPHATIC ESTER UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2002-03-26 US disclosed
US-6361766-B1 ANHYDROUS FORMULATION COMPRISING PARTICULATE ANTIPERSPIRANT SUSPENDED IN WATER-IMMISCIBLE CARRIER FLUID COMPRISING OXYGEN-CONTAINING EMOLLIENT OIL HAVING SPECIFIED REFRACTIVE INDEX STRUCTURED BY WAX OR NONPOLYMERIC FIBER-FORMING GELLANT UNILEVER HOME & PERSONAL CARE, USA DIVISION OF CONOPCO, INC. 2002-03-26 US disclosed
US-20020034481-A1 Antiperspirant formulations UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2002-03-21 US disclosed
EP-1180010-A1 ANTIPERSPIRANT COMPOSITIONS UNILEVER PLC (GB) 2002-02-20 EP disclosed
WO-2002011692-A1 ANTIPERSPIRANT FORMULATIONS UNILEVER PLC (GB) 2002-02-14 WO disclosed
WO-2002011691-A1 ANTIPERSPIRANT FORMULATIONS UNILEVER PLC (GB) 2002-02-14 WO disclosed
WO-2000074640-A1 ANTIPERSPIRANT COMPOSITIONS UNILEVER PLC (GB) 2000-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020034481-A1 Antiperspirant formulations ADH1A, SOAT1, CUTA TSHR 2742/4885PAM 2236/4885GPR84 1024/4885
US-20140193471-A1 SOLID ANTIPERSPIRANT AND/OR DEODORANT COMPOSITION IN THE FORM OF A WATER-IN-OIL EMULSION BASED ON SILICONE EMULSIFIERS AND ON WAXES; METHOD FOR TREATING BODY ODOURS DGAT1, DGAT2, DDT TSHR 2878/4885PAM 3373/4885GPR84 485/4885
US-10555878-B2 Solid antiperspirant and/or deodorant composition in the form of a water-in-oil emulsion based on silicone emulsifiers and on waxes; method for treating body odours DGAT1, DGAT2, DDT TSHR 2878/4885PAM 3373/4885GPR84 485/4885
US-20020039563-A1 Antiperspirant formulations ADH1A, SOAT1, CUTA TSHR 2794/4885PAM 1752/4885GPR84 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.